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EDITORIAL
IMPORTANT INFECTIOUS DISEASES IN THE LAST DECADE
Temenuga Stoeva
Department of Microbiology and Virology, Medical University of Varna 
Despite the remarkable advances in medical research and treatment during the 20th century, infectious 
diseases remain among the leading causes of death worldwide. In a recent survey by the World Health 
Organization, three infectious diseases are ranked in the top ten causes of death globally – lower respiratory tract 
infections (3.1 million deaths; 5.5%), HIV/AIDS (1.5 million deaths; 2.7%) and diarrheal diseases (1.5 million 
deaths; 2.7%). In low-income and lower-middle income countries, malaria and tuberculosis account for 
an additional two of the major ten causes of death and during the period 2014-2015 are responsible for 
438 000 and 1.5 million deaths, respectively (12). In addition to these, vaccine-preventable childhood 
diseases, meningitis, sexually transmitted infections (other than HIV), Hepatitis B and C, dengue 
and tropical disease also contribute significantly to the morbidity and mortality rates associated with 
infectious diseases (10).
During the last decade the European Center for Disease Prevention and Control (ECDC) monitors 
the epidemiology of more than 50 communicable diseases of public health importance in Europe 
and provides an annual picture and analysis of the state of these infections and threats detected in 
Europe. The major infectious diseases under surveillance are respiratory diseases, sexually transmitted 
infections (incl. HIV and blood born viruses), food and waterborne diseases, emerging and vector-
born, vaccine-preventable diseases, as well as antimicrobial resistance and healthcare-associated 
infections. The data from the last reports shows that respiratory tract infections, and particularly 
inf luenza, continue to cause a significant burden, especially to older individuals, very young children 
and subjects with chronic diseases. In the autumn of 2012 the first few cases in Europe of an emerging 
respiratory virus, that later became known as the Middle East respiratory syndrome coronavirus (MERS 
CoV), were identified (3). Tuberculosis remains a common infection and an important public health problem 
in the EU, with more than 68 000 cases reported annually. The highest rates are reported by Romania (85.2 per 
100000 population), Lithuania (59.2), Latvia (48.6) and Bulgaria (31.1) (4). Regarding the STIs, infection with 
the bacterium Chlamydia trachomatis remains the most frequently reported sexually transmitted infection 
in Europe, where it is also the highest–ranking reportable disease. In 2012, 384 105 cases of chlamydia were 
reported in 25 EU Member States, an overall rate of 199 per 100 000 population. Most chlamydial infections are 
asymptomatic and complications mostly affect women, including pelvic inflammatory disease, chronic pelvic 
pain and reduced fertility. In addition, Chlamydia trachomatis is a co-factor for HIV infection, increasing both 
susceptibility and infectiousness (2,6). In this aspect, HIV infection remains a major public health concern 
in Europe. The overall reported incidence has stabilized at around 29 000 cases annually, but reported rates 
continue to increase in many countries and vary widely between countries. The countries with the highest 
rates of HIV cases for 2014 are Estonia (23.6), Latvia (16.6), Belgium (11.1), Luxemburg (10.3) and the United 
Kingdom (10.1). The lowest rate is reported by Slovakia (0.9) (6). In the European context, the vector-borne 
diseases also pose a continuing and increasing public health risk. Locally acquired cases of diseases, previously 
considered to be only imported (malaria, dengue fever, chikungunya fever), continue to occur. The outbreak 
in Madeira in 2012 is the first major outbreak of dengue fever (with over 2 000 cases) in the recent history, in 
an EU country, and illustrates the potential for local transmission where competent insect vectors are present 
(2). Antimicrobial resistance in association with hospital-acquired infections is another major public health 
problem in Europe. It is estimated that within the EU healthcare system, 4.2 million patients each year are 
affected by healthcare-associated infections (HAIs). The main types of HAIs are respiratory tract infections 
(31.2%), urinary tract infections (31.2%) and skin infections (22.8%) (5).
Among the major non-communicable diseases, cancer is a leading cause of morbidity and mortality 
worldwide, with approximately 14 million new cases and 8.2 million cancer-related deaths in 2012 (9, 11). It is 
expected that annual cancer cases will rise from 14 million in 2012 to 22 million within the next 2 decades (1). 
Specific infections are recognized as a major cause of cancer, with an estimated 2 million (16.1%) of the 12.7 
million new cases of cancer in 2008 attributable to infection (11). The most important infectious agents are 
Helicobacter pylori, Hepatitis B and C viruses and Human papillomaviruses, which together are responsible for 
1.9 million cases of gastric, liver and cervix uteri cancers, respectively (1). In addition to these infectious agents, 
Opisthorchis viverrini, Clonorchis sinensis, Epstein-Barr virus, human T-cell lymphotropic virus type 1, human 
herpes virus type 8 (known as Kaposi’s sarcoma herpes virus) and Schistosoma haematobium are classified as 
carcinogenic to humans. 
As a reference to the significance of the infectious diseases nowadays, in this current issue of the journal, 
T. Kostadinova (7) and E. Kovachev (8) are focusing on two medically important microbial agents – Chlamydia 
trachomatis and Epstein-Barr virus. T. Kostadinova presents the current knowledge about the mechanisms 
of EBV pathogenesis in humans and its oncogenic potential. E. Kovachev reveals the relationship between 
Chlamydia trachomatis infection and pregnancy complications. 
In conclusion, in the next decade the infectious diseases (incl. new and re-emergence of old infectious 
diseases) are expected to remain a serious challenge for detection and monitoring, prevention, control and 
adequate treatment. 
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